Prelude Therapeutics (PRLD) Amortization of Deferred Charges (2021 - 2026)
Prelude Therapeutics (PRLD) reported Amortization of Deferred Charges of $387000.0 for Q1 2026, up 0.78% on a YoY basis from $384000.0 in Q1 2025, and up 0.78% sequentially from $384000.0 in Q4 2025.
Prelude Therapeutics (PRLD) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 6 years of Amortization of Deferred Charges data on file, last reported at $387000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 0.78% year-over-year to $387000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (down 1.54% YoY), and the FY2025 full-year result was $1.5 million, down 3.58% from the prior year.
- Amortization of Deferred Charges climbed to $387000.0 in Q1 2026, from $384000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $608000.0 in Q4 2023 to a low of $383000.0 in Q2 2025.
- A 5-year average of $421529.4 and a median of $411000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges jumped 48.62% in 2022 and slumped 36.18% in 2024, its largest moves.
- Tracing PRLD's Amortization of Deferred Charges over 5 years: stood at $437000.0 in 2022, then jumped by 39.13% to $608000.0 in 2023, then tumbled by 36.18% to $388000.0 in 2024, then slipped by 1.03% to $384000.0 in 2025, then rose by 0.78% to $387000.0 in 2026.
- Business Quant data shows PRLD's Amortization of Deferred Charges at $387000.0 in Q1 2026, $384000.0 in Q4 2025, and $383000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 387,000.00 |
| Mar 31, 2026 | 387,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Sep 30, 2025 | 383,000.00 |
| Sep 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 384,000.00 |
| Mar 31, 2025 | 384,000.00 |
| Dec 31, 2024 | 388,000.00 |
| Dec 31, 2024 | 388,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 397,000.00 |
| Mar 31, 2024 | 414,000.00 |
| Mar 31, 2024 | 414,000.00 |
| Dec 31, 2023 | 608,000.00 |
| Dec 31, 2023 | 608,000.00 |